AstraZeneca continued to see strong earnings boosted primarily by its oncology branch, as well as its respiratory and immunology segment.
Trending
- EU ban on BPA chemical in food packaging takes effect
- New video game console aims to get kids moving
- I tried the most advanced BBQ ever that cooks food way faster and leaves meat super juicy
- Wees niet zuinig met zonnebrand: ‘Voor je gezicht heb je al halve theelepel nodig’
- How to keep children cool in the heat
- Cuba: Between charcoal and solar panels | Renewable Energy
- World Cup 2026: Turkey crash out after 1-0 defeat to ten-man Paraguay
- Germany’s 2026 World Cup squad built on African roots
